PharmaCyte shareholders approve 50B common share authorization increase and bylaw amendment

PharmaCyte Biotech, Inc.

Authorized common stock increased to 50 billion shares ($0.0001 par); preferred stock to 10 million shares.
All seven director nominees elected; broker non-votes of ~701M shares.
2021 Equity Incentive Plan approved: 565.7M for, 116.4M against, 20.6M abstain.
Armanino LLP ratified as independent auditor for FY ending April 30, 2022.
Bylaw Amendment No. 4 adopted, adding cumulative voting rights for directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.